These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31927041)

  • 1. An NMR-Based Similarity Metric for Higher Order Structure Quality Assessment Among U.S. Marketed Insulin Therapeutics.
    Wang D; Park J; Patil SM; Smith CJ; Leazer JL; Keire DA; Chen K
    J Pharm Sci; 2020 Apr; 109(4):1519-1528. PubMed ID: 31927041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products.
    Wang D; Zhuo Y; Karfunkle M; Patil SM; Smith CJ; Keire DA; Chen K
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemometric Methods to Quantify 1D and 2D NMR Spectral Differences Among Similar Protein Therapeutics.
    Chen K; Park J; Li F; Patil SM; Keire DA
    AAPS PharmSciTech; 2018 Apr; 19(3):1011-1019. PubMed ID: 29110294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of 2D-NMR with room temperature NMR probes for the assessment of the higher order structure of filgrastim.
    Brinson RG; Ghasriani H; Hodgson DJ; Adams KM; McEwen I; Freedberg DI; Chen K; Keire DA; Aubin Y; Marino JP
    J Pharm Biomed Anal; 2017 Jul; 141():229-233. PubMed ID: 28454057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher-Order Structure Characterization of Pharmaceutical Proteins by 2D Nuclear Magnetic Resonance Methyl Fingerprinting.
    Haxholm GW; Petersen BO; Malmstrøm J
    J Pharm Sci; 2019 Sep; 108(9):3029-3035. PubMed ID: 31082403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Principal component analysis for automated classification of 2D spectra and interferograms of protein therapeutics: influence of noise, reconstruction details, and data preparation.
    Brinson RG; Elliott KW; Arbogast LW; Sheen DA; Giddens JP; Marino JP; Delaglio F
    J Biomol NMR; 2020 Nov; 74(10-11):643-656. PubMed ID: 32700053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principal Component Analysis of 1D 1H Diffusion Edited NMR Spectra of Protein Therapeutics.
    Elliott KW; Delaglio F; Wikström M; Marino JP; Arbogast LW
    J Pharm Sci; 2021 Oct; 110(10):3385-3394. PubMed ID: 34166704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid-State NMR Characterization of Lyophilized Formulations of Monoclonal Antibody Therapeutics.
    Perodeau J; Arbogast LW; Nieuwkoop AJ
    Mol Pharm; 2023 Mar; 20(3):1480-1489. PubMed ID: 36702622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Liquid-State and Solid-State Nuclear Magnetic Resonance at Natural Abundance for Comparative Higher Order Structure Assessment in the Formulated-State of Biphasic Biopharmaceutics.
    Pujahari SR; Mali PS; Purusottam RN; Kumar A
    Anal Chem; 2023 Jun; 95(22):8469-8477. PubMed ID: 37154614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple NMR methods for evaluating higher order structures of monoclonal antibody therapeutics with quinary structure.
    Chen K; Long DS; Lute SC; Levy MJ; Brorson KA; Keire DA
    J Pharm Biomed Anal; 2016 Sep; 128():398-407. PubMed ID: 27344629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Higher-Order Structure of Formulated Monoclonal Antibody Therapeutics by 2D Methyl Correlated NMR and Principal Component Analysis.
    Arbogast LW; Delaglio F; Brinson RG; Marino JP
    Curr Protoc Protein Sci; 2020 Jun; 100(1):e105. PubMed ID: 32407007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2D J-correlated proton NMR experiments for structural fingerprinting of biotherapeutics.
    Brinson RG; Marino JP
    J Magn Reson; 2019 Oct; 307():106581. PubMed ID: 31499472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics.
    Brinson RG; Marino JP; Delaglio F; Arbogast LW; Evans RM; Kearsley A; Gingras G; Ghasriani H; Aubin Y; Pierens GK; Jia X; Mobli M; Grant HG; Keizer DW; Schweimer K; Ståhle J; Widmalm G; Zartler ER; Lawrence CW; Reardon PN; Cort JR; Xu P; Ni F; Yanaka S; Kato K; Parnham SR; Tsao D; Blomgren A; Rundlöf T; Trieloff N; Schmieder P; Ross A; Skidmore K; Chen K; Keire D; Freedberg DI; Suter-Stahel T; Wider G; Ilc G; Plavec J; Bradley SA; Baldisseri DM; Sforça ML; Zeri ACM; Wei JY; Szabo CM; Amezcua CA; Jordan JB; Wikström M
    MAbs; 2019 Jan; 11(1):94-105. PubMed ID: 30570405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy.
    Amezcua CA; Szabo CM
    J Pharm Sci; 2013 Jun; 102(6):1724-1733. PubMed ID: 23568791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemometric Outlier Classification of 2D-NMR Spectra to Enable Higher Order Structure Characterization of Protein Therapeutics.
    Sheen DA; Shen VK; Brinson RG; Arbogast LW; Marino JP; Delaglio F
    Chemometr Intell Lab Syst; 2020; 199():. PubMed ID: 34135539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best Practices in Utilization of 2D-NMR Spectral Data as the Input for Chemometric Analysis in Biopharmaceutical Applications.
    Brinson RG; Arbogast LW; Marino JP; Delaglio F
    J Chem Inf Model; 2020 Apr; 60(4):2339-2355. PubMed ID: 32249579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best Practices for Submission of NMR Data to Support Higher Order Structure Assessment of Generic Peptide Drugs.
    Chen K; Smith CJ
    AAPS J; 2023 Jan; 25(1):17. PubMed ID: 36670271
    [No Abstract]   [Full Text] [Related]  

  • 18. A Comparison Between Emerging and Current Biophysical Methods for the Assessment of Higher-Order Structure of Biopharmaceuticals.
    Wen J; Batabyal D; Knutson N; Lord H; Wikström M
    J Pharm Sci; 2020 Jan; 109(1):247-253. PubMed ID: 31669605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the Analytical Superiority of 1D NMR for Fingerprinting the Higher Order Structure of Protein Therapeutics Compared to Multidimensional NMR Methods.
    Poppe L; Jordan JB; Rogers G; Schnier PD
    Anal Chem; 2015 Jun; 87(11):5539-45. PubMed ID: 25929316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.